IMPACT Therapeutics Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Revenue	118.21	38.25	33.55
Revenue Growth	-	14.02%	-
Cost of Revenue	10.7	1.57	1.56
Gross Profit	107.51	36.68	31.99
Selling, General & Admin	121.65	82.98	44.93
Research & Development	194.97	183.67	194.81
Other Operating Expenses	12.21	3.53	3.81
Operating Expenses	328.83	270.18	243.55
Operating Income	-221.33	-233.5	-211.56
Interest Expense	-59.44	-68.66	-55.56
Interest & Investment Income	6.6	6.85	9.39
Currency Exchange Gain (Loss)	-10.74	-2.05	1.98
Other Non Operating Income (Expenses)	26.72	1.24	0.93
EBT Excluding Unusual Items	-258.19	-296.12	-254.82
Gain (Loss) on Sale of Investments	-0.02	-	0.07
Gain (Loss) on Sale of Assets	0.21	0.2	-
Pretax Income	-258	-295.92	-254.75
Income Tax Expense	0	0	0
Net Income	-258	-295.92	-254.76
Net Income to Common	-258	-295.92	-254.76
Net Income Growth	-	-	-
Shares Outstanding (Basic)	240	229	201
Shares Outstanding (Diluted)	240	229	201
Shares Change	-	13.99%	-
EPS (Basic)	-1.07	-1.29	-1.27
EPS (Diluted)	-1.07	-1.29	-1.27
EPS Growth	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Free Cash Flow	-102.1	-97.39	-83.01
Free Cash Flow Per Share	-0.42	-0.43	-0.41
Gross Margin	90.95%	95.89%	95.36%
Operating Margin	-187.24%	-610.43%	-630.63%
Profit Margin	-218.27%	-773.64%	-759.40%
Free Cash Flow Margin	-86.38%	-254.61%	-247.43%
EBITDA	-220.3	-232.44	-210.02
D&A For EBITDA	1.02	1.05	1.54
EBIT	-221.33	-233.5	-211.56